ATRC logo

ATRICURE INC

ATRCNASDAQ
๐Ÿ† #1624 by market capEarnings Oct 27 ยท PostUS Equity
$42.95โ–ฒ $1.35 (+3.15%)
Market closed ยท at close
1hโ€”
24hโ–ฒ 3.1%
7dโ–ฒ 9.1%
14dโ–ฒ 5.1%
30dโ–ฒ 23.3%
1yโ–ฒ 19.7%
๐ŸฆMarket Cap
$2.18B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+14.9%
Healthy
๐Ÿ“ŠGross Margin
76.2%
High
๐Ÿ’ตFCF Margin
10.2%
Healthy
โš–๏ธP/S Ratio
3.8x
Fair
Otter Score
53
Weak

Trading Snapshot

Day Range
$42.77 โ€“ $43.73
52-Week Range
$25.36 โ€“ $43.18
Volume
$5.94B
Avg Volume
$6.42B
Shares Outstanding
50.9M
Next Earnings
Oct 17, 2026

Fundamentals Snapshot

Annual Revenue
$535M
Last Q Revenue
$154M
P/E Ratio
202.4
P/S Ratio
3.8x
EPS (TTM)
$0.22
Dividend Yield
0.00%

Why Investors Own ATRC

  • โœ“High-growth profile โ€” revenue up -5.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 49% gross margin and 29% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$535Mโ–ผ โˆ’7.5% YoY
Gross Margin (TTM)
49.0%โ–ผ โˆ’0.1% YoY
Operating Income (TTM)
$142Mโ–ผ โˆ’7.5% YoY
Free Cash Flow (TTM)
$153Mโ–ผ โˆ’7.5% YoY

About ATRICURE INC

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
53/100

Analyst Ratings

โ“˜
Consensus
Buy
16 analysts
Strong Buy4
Buy9
Hold3
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

Yahooยท4d ago

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

Yahooยท4d ago

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

Benzingaยท4d ago

Director At AtriCure Sells $134K Of Stock

It was reported on August 7, that Maggie Yuen, Director at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and

Yahooยท7d ago

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Benzingaยท11d ago

Insider Selling: Vinayak Doraiswamy Unloads $233K Of AtriCure Stock

It was reported on July 30, that Vinayak Doraiswamy, Chief Scientific Officer at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with

Benzingaยท11d ago

Board Member At AtriCure Exercises Options Worth $491K

A significant insider transaction involving the exercise of company stock options was reported on July 30, by Sven Wehrwein, Board Member at AtriCure (NASDAQ:ATRC), as per the latest SEC filing. What Happened: A Form 4